Efficacy of gemcitabine in combination with nanoparticle a lbumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review
Cancer Medicine · 2023
DOI: 10.1002/cam4.5705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Adam M Kase und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The objective of this study was to evaluate the efficacy of gemcitabine plus nab‐paclitaxel in patients with recurrent ovarian cancer.
Methods
We performed a single institution retrospective review of patients with recurrent ovarian cancer who were treated with gemcitabine plus nab‐paclitaxel from 2012 to 2018 at the Mayo Clinic in Florida.
Results
Twenty patients were identified and the median PFS for patients treated with gemcitabine plus nab‐paclitaxel was 9 months (95% CI, 5.7–20.7). Overall, 17 of the 20 patients (85%) achieved a clinical benefit (complete response 5%, partial response 55%, or stable disease at 3 months 25%). For platinum‐sensitive disease and platinum‐resistant disease, the median OS were 38.7 months (95% CI, 5.8–63.1) and 31.2 months (95% CI, 12.8–51.8), respectively ( p = 0.4306).
Conclusion
This well‐tolerated regimen shows promising activity in recurrent ovarian cancer and is a viable option for patients who are intolerant to paclitaxel or carboplatin because of allergic reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
- Cancer Care Institute, Monument Health, Rapid City, South Dakota, USA.
ORCID-Profile: Adam M Kase
Förderung
- NCI NIH HHS
Zitieren
APA
Kase, A. M., Azzouqa, A. G., Kochuveettil, S., & Colon-Otero, G. (2023). Efficacy of gemcitabine in combination with nanoparticle a lbumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review. Cancer Medicine. https://doi.org/10.1002/cam4.5705
Vancouver
Kase AM, Azzouqa AG, Kochuveettil S, Colon-Otero G. Efficacy of gemcitabine in combination with nanoparticle a lbumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review. Cancer Medicine. 2023. doi:10.1002/cam4.5705
BibTeX
@article{Kase2023,
author = {Kase, Adam M and Azzouqa, Abdel-Ghani and Kochuveettil, Swapna and Colon-Otero, Gerardo},
title = {Efficacy of gemcitabine in combination with nanoparticle a lbumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5705}
}
EUVIMED